Company intelligence / Profile preview

ForSeeCon Eye

Ownership: Private
Development stage: Other

Overview

Early clinical studies of Vitargus indicate unique properties that may eliminate the need for face-down positioning after eye surgery and significantly improve patient comfort and visual acuity. Safety and efficacy have been demonstrated with no evidence of treatment-related toxicity. Pivotal international trials are planned for 2025.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

ABVC BioPharmaBioFirst

Beyond the preview

Go deeper on ForSeeCon Eye.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ForSeeCon Eye.

Explore the full profile